

Market Applicability														
Market	DC	FL & FHK	FL MMA	FL LTC	GA	KS	KY	MD	NJ	NV	NY	TN	TX	WA
Applicable	X	X	NA	NA	X	NA	X	X	X	X	X	NA	NA	X

*FHK- Florida Healthy Kids

Cometriq (cabozantinib)

Override(s)	Approval Duration
Prior Authorization Quantity Limit	1 year

Medications	Quantity Limit
Cometriq (cabozantinib) 20mg	3 capsules per day
Cometriq (cabozantinib) 80mg	1 capsule per day
Cometriq (cabozantinib) 60mg daily-dose pack	1 dose pack (84 capsules per 28 days)
Cometriq (cabozantinib) 100mg daily-dose pack	1 dose pack (56 capsules per 28 days)
Cometriq (cabozantinib) 140mg daily-dose pack	1 dose pack (112 capsules per 28 days)

APPROVAL CRITERIA

Requests for Cometriq (cabozantinib) may be approved if the following criteria are met:

I. Individual has a diagnosis of progressive, metastatic medullary thyroid cancer (MTC);

OR

II. Individual has a diagnosis of Follicular, Papillary, or Hurthle Cell thyroid carcinomas (NCCN 2A); **AND**

III. Other systemic therapies or clinical trials are unavailable or appropriate for treatment of progressive and/or symptomatic iodine-refractory disease (NCCN 2A);

OR

IV. Individual has a diagnosis of Non-Small Lung Cancer with RET gene rearrangements (NCCN 2A).

Note: Cometriq (cabozantinib) has black box warnings for perforations and fistulas and hemorrhage. Gastrointestinal (GI) perforations, fistula formation, and severe hemorrhage have occurred in individuals treated with Cometriq. Discontinue therapy for GI perforation or fistula formation. Monitor individuals for bleeding, and do not administer in individuals with severe hemorrhage.

This policy does not apply to health plans or member categories that do not have pharmacy benefits, nor does it apply to Medicare. Note that market specific restrictions or transition-of-care benefit limitations may apply.

Market Applicability														
Market	DC	FL & FHK	FL MMA	FL LTC	GA	KS	KY	MD	NJ	NV	NY	TN	TX	WA
Applicable	X	X	NA	NA	X	NA	X	X	X	X	X	NA	NA	X

*FHK- Florida Healthy Kids

State Specific Mandates		
State name	Date effective	Mandate details (including specific bill if applicable)
N/A	N/A	N/A

Key References:

Clinical Pharmacology [database online]. Tampa, FL: Gold Standard, Inc.: 2018. URL: <http://www.clinicalpharmacology.com>. Updated periodically.

DailyMed. Package inserts. U.S. National Library of Medicine, National Institutes of Health website. <http://dailymed.nlm.nih.gov/dailymed/about.cfm>.

DrugPoints® System (electronic version). Truven Health Analytics, Greenwood Village, CO. Updated periodically.

Lexi-Comp ONLINE™ with AHFS™, Hudson, Ohio: Lexi-Comp, Inc.; 2018; Updated periodically.

The NCCN Drugs & Biologics Compendium (NCCN Compendium™) © 2018 National Comprehensive Cancer Network, Inc. Available at: NCCN.org. Updated periodically.

This policy does not apply to health plans or member categories that do not have pharmacy benefits, nor does it apply to Medicare. Note that market specific restrictions or transition-of-care benefit limitations may apply.